- Company
- AstraZeneca objected to the second judgment of Forxiga
- by Kim, Jin-Gu Nov 4, 2020 06:08am
- AstraZeneca lost the second trial of Forxiga's material patent. And AstraZeneca announced that it would appeal to the Supreme Court. AstraZeneca said in a separate statement on the 30th that it disobeyed the judgment of the Patent Court of Korea on the 29th. The Patent Court of Korea sided with 19 companies including Kukje Pharma in a law
- Company
- Opdivo resumes indication expansion in NSCLC as first-line
- by Eo, Yun-Ho Nov 3, 2020 05:58am
- The pharmaceutical industry sources reported Ono Pharmaceutical and Bristol Myers Squibb (BMS) have recently submitted an application to expand indication on a programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in combination with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibitor Yervoy
- Policy
- Daewoong's DWP16001 targets synergistic effect with Zemiglo
- by Lee, Tak-Sun Nov 3, 2020 05:58am
- Daewoong's new SGLT-2 inhibitory diabetes drug candidate is aiming for synergy with another domestic drug. The drug, first designated for expedited review, has been approved for three phase III clinical trials. The MFDS approved a phase III clinical trial protocol for Daewoong Pharmaceutical's new diabetes drug candidate 'DWP16001 (Enavog
- Company
- The Korean MSD union opposes the spin-off of Organon
- by Nov 3, 2020 05:58am
- MSD Korea's labor union begins full-scale dispute activities ahead of the spin-off of Organon. The representative group for bargaining of MSD Korea and the MSD branch of the Korea Democratic Pharmaceutical Union (KDPU) held votes for and against the industrial action for each member on the 28th to 29th. As a result, both unions approved t
- Policy
- Merck green lit to test novel COVID-19 antiviral in Korea
- by Lee, Tak-Sun Nov 3, 2020 05:58am
- A novel COVID-19 antiviral candidate, currently in development by a U.S.-based pharmaceutical company Merck, is to conduct a clinical trial in South Korea. Previously, Bloomberg covered the novel candidate as a ‘potential game-changer in the COVID-19 therapeutic scene. On Oct. 29, the Ministry of Food and Drug Safety (MFDS) has appr
- Policy
- 1 out of 4 claims for unltra priced Spinraza were approved
- by Lee, Hye-Kyung Nov 3, 2020 05:58am
- Only one out of four applications for pre-approval for salary medication 'Spinraza (Nusinersen)', a treatment for Spinal Muscular Atropy (SMA), was approved last month. The remaining one can be approved conditionally, and two have to be supplemented with data. A monitoring report must be submitted before administration of maintenance dose
- Company
- Roche: Fast listing was all about improving patient access
- by Eo, Yun-Ho Nov 2, 2020 06:13am
- An anticancer treatment specializing pharmaceutical company, Roche has been viewed to stand relatively “aloof” from seeking the health insurance reimbursement. But now Roche seems to be picking up its speed. Their last two years have been different; the company successfully expanded the reimbursement on targeted therapy Alecensa in anap
- Policy
- Hyundai is preparing for domestic approval of Mifegyne
- by Lee, Jeong-Hwan Nov 2, 2020 06:13am
- Hyundai Pharm, which maintains the No. 1 market share in the emergency (post) contraceptives market, is preparing for the domestic market approval of the artificial abortion drug Mifegyne. Mifegyne was ruled by the Constitutional Court for an abortion inconsistency in April last year, and the need to legalize domestic use and interest in
- Company
- 19 Korean companies partially win Forxiga patent dispute
- by Kim, Jin-Gu Nov 2, 2020 06:13am
- A South Korean court ruled in favor of the generic companies in an appeal case for a patent dispute on an antidiabetic sodium-glucose co-transporter-2 (SGLT2) inhibitor Forxiga (dapagliflozin). The original company AstraZeneca lost another patent litigation in a higher court after losing from the Intellectual Property Trial and Appeal Board
- Policy
- Special agreement for re-evaluation of α-GPC is urgent
- by Lee, Jeong-Hwan Nov 2, 2020 06:12am
- Nam In-soon, a member of Democratic Party of Korea, stressed that there is a need for a 'special contract to return the reimbursement price' between the NHIS and pharmaceutical companis that applied for the clinical re-evaluation of Choline alfoscerate. In clinical reevaluation, a pharmaceutical company that failed to prove the usefulness
